Geron Corporation Presents Data at International Society for Stem Cell Research Showing that its Embryonic Stem Cell Therapeutic for Heart Failure Evades Direct Attack by the Human Immune System
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company’s human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by the human immune system in vitro.